Search results for: 25mg
#39372842 
2024/07/24
To Up
Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
Functional neurological disorder (FND) is a common cause of neurological symptoms including paralysis, seizures, and movement disorders. It is often debilitating, is associated with high health and social care costs, and can have a poor prognosis. Functional magnetic resonance imaging (fMRI) has suggested FND is a multi-network disorder; the default mode network (DMN) may be specifically implicated. Converging evidence suggests that other variable mechanisms including dissociation, interoception, and motor agency may be differentially abnormal in people with FND. Psychedelics are currently under investigation for numerous neuropsychiatric disorders and have been shown to disrupt functional networks such as the DMN. Administering psychedelics to people with FND will help us to probe mechanistic theories of the disorder.Matt Butler, Catherine Bird, Carolina Maggio, Amy Durden, Nadav Modlin, Kete Campbell-Coker, Mark Edwards, Susannah Pick, L S Merritt Millman, Emily Lowery, Chiranth Bhagavan, Richard Kanaan, Dawn Golder, Bridget Mildon, Mitul Mehta, James Rucker, Timothy R Nicholson
2746 related Products with: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
1 kit(96 Wells)11 kit(96 Wells)1 mg1 kit(96 Wells)100 μg100 mg50
Related Pathways
#39301161 2024/09/05
To Up
Preliminary establishment of genetic transformation system for embryogenic callus of 'Lihong'.
Bunge, belonging to the Acer genus in the Aceraceae family, is a commonly planted afforestation species across China, Japan, Korea, Europe, and North America. Renowned for its vibrant fall colors, it holds significant ecological and ornamental value.Yipeng Yang, Yuan Chan, Yongge Wang, Hao Guo, Lina Song, Huali Zhang, Liping Sun, Richen Cong, Hua Zhang
2512 related Products with: Preliminary establishment of genetic transformation system for embryogenic callus of 'Lihong'.
5 G 70 Slides 250 mg120 ug 1 G 500 Slides 1 ml1 each 70 Slides 10 ml
Related Pathways
-
No related Items
#39278350 2024/09/13
To Up
Probable chlorthalidone-induced hypokalemic rhabdomyolysis.
A case of hypokalemic rhabdomyolysis related to chlorthalidone use is reported SUMMARY: A 52-year-old male was admitted to the hospital for acute onset generalized weakness and was found to have severe hypokalemia and rhabdomyolysis. The patient had been on chlorthalidone therapy with a dose increase from 25mg daily to 50mg daily two months prior to admission. Extensive workup ruled out neurologic, rheumatologic and endocrinologic causes of hypokalemia. In the absence of other causes, it was determined that the patient was experiencing a severe presentation of chlorthalidone-induced hypokalemia resulting in rhabdomyolysis. The patient's rhabdomyolysis and weakness improved with aggressive potassium correction, and potassium wasting eventually resolved with discontinuation of chlorthalidone.Gagandeep Singh, Caitlin Canton, Diana Langworthy
2048 related Products with: Probable chlorthalidone-induced hypokalemic rhabdomyolysis.
50 ul1 mg 100ul100ug5ug2ug100ug100 ul400 ug96 assays100 ul400 ug
Related Pathways
#39236082 2024/09/05
To Up
Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax.
Radical cure of Plasmodium vivax infections is key to the control of vivax malaria. However, the standard doses of 8-aminoquinoline drugs used for radical cure can cause severe haemolysis in G6PD-deficient patients. The availability of near-patient G6PD tests could increase use of primaquine (PQ), however direct evidence of the impacts that G6PD testing has on downstream patient outcomes, such as haemolysis and recurrence is lacking.Michelle L Gatton
2808 related Products with: Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax.
1 mg50 200 200 1 mg 5 G 500 ml 5 mg1 g100 tests1 mg
Related Pathways
#39228633 2024/07/26
To Up
Falling into complexity: A case of digitalis-induced fall, trauma, symptomatic bradycardia, and syncope.
Digoxin, a cardiac glycoside, functions by inhibiting the sodium potassium ATPase pump. It's crucial to note that digoxin has a very narrow therapeutic range. Its serum level vary due to changes in body weight, age, renal function, hepatic impairment and concomitant drug therapy. Chronic toxicity can lead to different types of arrrythmia,which span from heart blocks to ventricular tachycardia. This report present a case of an elderly male, where Digoxin toxicity resulted in syncope and mild traumatic brain injury. Initially upon patient's presentation ECG indicated myocardial infarction, subsequently bradycardia and complete heart block. The patient had a known history of chronic kidney disease and was prescribed 0.25mg of digoxin regularly without dose adjustment, which might have resulted in reduced digoxin elimination, leading to toxicity. Thus this case demonstrates a classic presentation of digoxin toxicity. Multiple risk factor such as old age, impaired renal function with continued digoxin treatment without dose adjustment was likely the cause of toxicity.Rajathadri H Ravikumar, Baby Pegu, Himanti Bansal, Kapil Dev Soni
1151 related Products with: Falling into complexity: A case of digitalis-induced fall, trauma, symptomatic bradycardia, and syncope.
100ug
Related Pathways
#39225259 2024/09/02
To Up
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides.Gerald F Watts, Robert S Rosenson, Robert A Hegele, Ira J Goldberg, Antonio Gallo, Ann Mertens, Alexis Baass, Rong Zhou, Ma'an Muhsin, Jennifer Hellawell, Nicholas J Leeper, Daniel Gaudet,
2322 related Products with: Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.
2.5 mg 100ul10 200ug100ug200 mg2000 rxn10 mg25 g250 ml
Related Pathways
#39116687 2024/07/27
To Up
Neural correlates of treatment response to ketamine for treatment-resistant depression: A systematic review of MRI-based studies.
Treatment-resistant depression (TRD) is defined as patients diagnosed with depression having a history of failure with different antidepressants with an adequate dosage and treatment duration. The NMDA receptor antagonist ketamine rapidly reduces depressive symptoms in TRD. We examined neural correlates of treatment response to ketamine in TRD through a systematic review of brain magnetic resonance imaging (MRI) studies. A comprehensive search in PubMed was performed using "ketamine AND depression AND magnetic resonance." The time span for the database queries was "Start date: 2018/01/01; End date: 2024/05/31." Total 41 original articles comprising 1,396 TRD and 587 healthy controls (HC) were included. Diagnosis of depression was made using the Structured Clinical Interview for DSM Disorders (SCID), the Mini-International Neuropsychiatric Interview (MINI), and/or the clinical assessment by psychiatrists. Patients with affective psychotic disorders were excluded. Most studies applied ketamine [0.5mg/kg racemic ketamine and/or 0.25mg/kg S-ketamine] diluted in 60cc of normal saline via intravenous infusion over 40 min one time, four times, or six times spaced 2-3 days apart over 2 weeks. Clinical outcome was defined as either remission, response, and/or percentage changes of depressive symptoms. Brain MRI of the T2*-weighted imaging (resting-state or task performance), arterial spin labeling, diffusion weighted imaging, and T1-weighted imaging were acquired at baseline and mainly 1-3days after the ketamine administration. Only the study results replicated by ≥ 2 studies and were included in the default-mode, salience, fronto-parietal, subcortical, and limbic networks were regarded as meaningful. Putative brain-based markers of treatment response to ketamine in TRD were found in the structural/functional features of limbic (subgenual ACC, hippocampus, cingulum bundle-hippocampal portion; anhedonia/suicidal ideation), salience (dorsal ACC, insula, cingulum bundle-cingulate gyrus portion; thought rumination/suicidal ideation), fronto-parietal (dorsolateral prefrontal cortex, superior longitudinal fasciculus; anhedonia/suicidal ideation), default-mode (posterior cingulate cortex; thought rumination), and subcortical (striatum; anhedonia/thought rumination) networks. Brain features of limbic, salience, and fronto-parietal networks could be useful in predicting the TRD with better response to ketamine in relief of anhedonia, thought rumination, and suicidal ideation.Je-Yeon Yun, Yong-Ku Kim